UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

AdoRx Therapeutics

AdoRx Therapeutics logo

AdoRx Therapeutics

BiotechnologyEdinburgh, United Kingdom

About AdoRx Therapeutics

Founded in Edinburgh in 2017, AdoRx Therapeutics is a clinical-stage oncology drug discovery company built around a single well-validated biological insight: high concentrations of adenosine within the tumour microenvironment allow cancer cells to evade immune surveillance. The company designs small-molecule adenosine receptor antagonists intended to disrupt that immune evasion and restore anti-tumour activity.

Pipeline and Scientific Platform

AdoRx focuses on two mechanistic targets: selective antagonists of the adenosine A2A receptor and dual-blockade compounds targeting both A2A and A2B receptors simultaneously. The dual-blockade approach is designed to address the redundancy that can limit single-target therapies in the adenosine pathway. The leadership team brings more than 60 years of combined drug-discovery experience across biotech and pharma, having collectively contributed to the identification of over 25 clinical candidates.

Funding and Partnerships

The company was seeded with $10 million in initial funding from Epidarex Capital and Sixth Element Capital, both specialist life-sciences investors. In 2019, AdoRx secured a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson, under which J&J received an exclusive option to research, develop and commercialise novel adenosine antagonists from the AdoRx portfolio. The partnership underscores the scientific and commercial credibility of the company's immuno-oncology platform.

Further information is available at adorx.com.

Areas of Expertise

Drug DiscoveryImmuno-oncologyOncologySmall Molecule Therapeutics

Services & Capabilities

Drug DiscoveryImmuno-oncologyOncologySmall Molecule Therapeutics
Similar Companies

More in Biotechnology

K

Kuros Biosciences

Kuros Biosciences pioneers biologic bone graft technologies designed to advance bone healing through the combination of innovation and clinical evidence. The Swiss-headquartered biotech company is listed on the SIX Swiss Exchange under the ticker KURN, with operations extending to the Netherlands and the United States. Central to its offering is the MagnetOs product family, a portfolio of bone graft solutions available in multiple formulations. For spinal applications, the range includes MagnetOs Easypack Putty, MagnetOs MIS, MagnetOs Flex Matrix, MagnetOs Putty and MagnetOs Granules. A parallel line addresses extremity indications, with products sharing the same core mechanism of action. The breadth of these formulations reflects a commitment to addressing both surgical access requirements and diverse anatomical targets across orthopaedic settings. Kuros supports clinicians and procurement specialists through a dedicated Evidence Hub, providing access to clinical research, a searchable bibliography and a global research summary. The company also enables direct engagement with clinical, medical and scientific affairs through an expert consultation pathway, signalling its orientation toward evidence-based adoption within the orthopaedic biologics sector. The leadership structure includes a board of directors, a clinical and scientific affairs team, and specialist strategic advisory boards for both the spine and extremities segments, reflecting the depth of clinical governance brought to product development and post-market activities. Further information is available at kurosbio.com.

View profile
M

Moderna

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna is a clinical-stage biotechnology company listed on the Nasdaq (ticker: MRNA) that has built its entire operation around a single scientific bet: that messenger RNA can be harnessed as a programmable medicine. Rather than developing one drug at a time, the company operates as an mRNA platform business, using the same underlying technology to generate candidates across vaccines, oncology, rare disease and cardiovascular indications. The mRNA Platform and Pipeline More than fifteen years of continuous mRNA research underpin Moderna's proprietary mRNA Design Studio, a discovery and development environment that allows scientists to design, iterate and optimise mRNA sequences with a speed that conventional small-molecule or biologics programmes cannot match. The platform has already produced two approved products: Spikevax, its COVID-19 vaccine authorised in multiple markets worldwide, and mRESVIA, an mRNA-based vaccine for respiratory syncytial virus approved by the US FDA in 2024 for adults aged 60 and over. A broad pipeline sits behind these approvals, including an investigational seasonal influenza vaccine (mRNA-1010), a personalised cancer vaccine programme developed in collaboration with Merck that uses individualised mRNA sequences to target tumour-specific neoantigens, and candidates targeting cytomegalovirus, latent HIV and rare metabolic disorders. Global Operations and Commercial Scale Moderna maintains country-specific commercial and regulatory operations across North America, Europe and Asia Pacific, with established presences in the United States, Canada, the United Kingdom, France, Germany, Italy, the Netherlands, Spain, Switzerland, Poland, Australia, Japan, South Korea, Hong Kong, Taiwan and Singapore. The company has received substantial non-dilutive funding through longstanding partnerships with US government agencies including BARDA and DARPA, which supported its early platform work. Investor relations, healthcare professional resources, supplier programmes and a clinical trials portal are all maintained as distinct operational functions, consistent with Moderna's scale as a multi-market biopharmaceutical organisation. Further information is available at modernatx.com.

View profile
A

Akari Therapeutics

At the forefront of a differentiated approach to cancer treatment, Akari Therapeutics is a Nasdaq-listed oncology biotechnology company (ticker: AKTX) developing a new class of antibody-drug conjugates (ADCs) built around a novel payload, PH1, that targets RNA splicing rather than the tubulin inhibitors or DNA-damaging agents used by existing ADC programmes. Headquartered in New York, the company operates a proprietary ADC discovery platform designed to generate and optimise candidates against any antigen target of interest. The lead programme, AKTX-101, is directed at the Trop2 receptor expressed on cancer cells. A proprietary linker enables AKTX-101 to deliver the PH1 payload directly into tumours with the aim of minimising off-target effects, differentiating it from first-generation ADC approaches that rely on tubulin or DNA-damaging payloads. Trop2 is a clinically validated target in multiple solid tumour indications, and Akari's RNA-splicing mechanism of action represents biology not yet exploited by currently approved ADC therapies. The next-generation ADC discovery platform is engineered to accelerate candidate generation and to tailor individual ADCs to specific oncology applications across multiple antigen targets. By combining a distinctive payload class with a flexible discovery engine, Akari positions itself within the broader precision oncology space as a company pursuing mechanistic differentiation from first-wave ADC programmes as its pipeline advances. Further information is available at akaritx.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy